Philip Niles, MD, MBA

Articles by Philip Niles, MD, MBA

Management of Patient Cost for Wet Age-Related Macular Degeneration

ByJim Kenney, RPh, MBA,Kevin U. Stephens, Sr, JD, MD ,Philip Niles, MD, MBA,Nicholas G. Anderson, MD

February 16th 2022

Kevin U. Stephens, Sr., JD, MD, leads a discussion exploring the key drivers of cost for patients with wet age-related macular degeneration (AMD).

Defining Diabetic Macular Edema

ByJim Kenney, RPh, MBA,Kevin U. Stephens, Sr, JD, MD ,Philip Niles, MD, MBA,Nicholas G. Anderson, MD

February 9th 2022

Nicholas G. Anderson, MD, and Philip Niles, MD, MBA, provide an overview of diabetic macular edema (DME) and the impact of vision impairment on a patient’s quality of life.

Overview of Wet Age-Related Macular Degeneration

ByJim Kenney, RPh, MBA,Kevin U. Stephens, Sr, JD, MD ,Philip Niles, MD, MBA,Nicholas G. Anderson, MD

February 9th 2022

Philip Niles, MD, MBA, and Nicholas G. Anderson, MD, define wet age-related macular degeneration (AMD) and review clinical manifestations of the disease.

Philip Niles, MD, MBA

Articles by Philip Niles, MD, MBA

Management of Patient Cost for Wet Age-Related Macular Degeneration

Defining Diabetic Macular Edema

Overview of Wet Age-Related Macular Degeneration

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD